NASDAQ OMX

Minerva Neurosciences Names Dr. Justine Lalonde as Senior Vice President, Product Strategy

Dela

WALTHAM, Mass., Oct. 31, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced the appointment of Dr. Justine Lalonde, M.D., M.B.A., as Senior Vice President, Product Strategy.  Dr. Lalonde's primary responsibility will be to optimize the portfolio strategy of Minerva based on a multidisciplinary approach that encompasses medical affairs, business development and market research.

Dr. Lalonde was previously Medical Director, Neurosciences for Roche France in Paris and served as senior International Medical Leader in global medical affairs at Roche in Basel, Switzerland, where she developed and directed pre-launch medical activities in the area of schizophrenia, especially negative symptoms. As part of the organization's cross-functional leadership team, her activities focused on product launch and positioning, clinical development plans, regulatory strategy, pricing, lifecycle management, brand development, labelling, personalized healthcare and scientific communication.  Prior to joining Roche's Global Product Strategy and Medical Affairs group, she was responsible for sourcing, due diligence and executing global R&D licensing agreements in neuroscience with Roche Pharma Partnering.  Dr. Lalonde formerly was at AstraZeneca Switzerland as marketing brand manager for Symbicort and sales manager for Seroquel.  Earlier, she was at Novartis Pharma, where she was involved in portfolio management.

Dr. Lalonde holds a doctor of medicine with honors from the University of Toronto and a masters of business administration from Harvard Business School.  She completed her specialty training at Harvard Medical School's Mass General Hospital and at the McLean Hospital residency program in adult psychiatry, as well as a fellowship in child psychiatry at Harvard-affiliated Cambridge Hospital.  At McLean Hospital, Dr. Lalonde was associate director, child and adolescent research, had a private practice focused on mood disorders and was a member of the McLean Hospital institutional review board.  She was an investigator in 18 industry and NIH-sponsored clinical trials, has authored 15 peer-review papers and over 20 posters and has presented research findings at international conferences.

"Dr. Lalonde brings broad and deep experience in the development, marketing and commercialization of innovative CNS products," said Dr. Remy Luthringer, president and chief executive officer of Minerva.  "We are excited to have her join the Minerva senior management team and look forward to her multidisciplinary contributions as our product candidates, led by MIN-101 for schizophrenia, proceed through later-stage clinical development."  

About Minerva Neurosciences

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a portfolio of products to treat CNS diseases.  Minerva's proprietary compounds include: MIN-101, in clinical development for schizophrenia; Seltorexant (MIN-202 or JNJ-42847922), in clinical development for insomnia and major depressive disorder (MDD); MIN-117, in clinical development for MDD; and MIN-301, in pre-clinical development for Parkinson's disease.  Minerva's common stock is listed on the NASDAQ Global Market under the symbol "NERV."  For more information, please visit www.minervaneurosciences.com.

Forward-Looking Safe Harbor Statement

This press release contains forward-looking statements which are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended.  Forward-looking statements are statements that are not historical facts, reflect management's expectations as of the date of this press release, and involve certain risks and uncertainties.  Forward-looking statements include statements herein with respect to the timing and scope of future clinical trials and results of clinical trials with MIN-101, Seltorexant, MIN-117 and MIN-301.  These forward-looking statements are based on our current expectations and may differ materially from actual results due to a variety of factors including, without limitation, whether MIN-101, Seltorexant, MIN-117 and MIN-301 will advance further in the clinical trials process; management's ability to successfully achieve its goals; our ability to raise additional capital to fund our operations on terms acceptable to us; and general economic conditions.  These and other potential risks and uncertainties that could cause actual results to differ from the results predicted are more fully detailed under the caption "Risk Factors" in our filings with the Securities and Exchange Commission, including our Quarterly Report on Form 10-Q for the quarter ended June 30, 2017, filed with the Securities and Exchange Commission on August 3, 2017.  Copies of reports filed with the SEC are posted on our website at  www.minervaneurosciences.com . The forward-looking statements in this press release are based on information available to us as of the date hereof, and we disclaim any obligation to update any forward-looking statements, except as required by law.

Contact:
William B. Boni
VP, Investor Relations/
Corp. Communications
Minerva Neurosciences, Inc.
(617) 600-7376




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Minerva Neurosciences, Inc. via Globenewswire

Om

NASDAQ OMX
NASDAQ OMX



Följ NASDAQ OMX

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från NASDAQ OMX

Fentress Architects: The Future of Airports as Civic Spaces21.5.2018 22:27Pressmeddelande

The European Cultural Centre and Global Art Affairs Foundation invited Fentress Architects and North Carolina State University College of Design to participate in the 2018 Venice Architecture Biennale May 26-November 25, 2018, at the historic Palazzo Bembo. Denver, Colo. - May 21, 2018, May 21, 2018 (GLOBE NEWSWIRE) -- Architecture students from North Carolina State University College of Design will join Fentress at the Palazzo Bembo to present their designs for airports of the future. Fentress has been guiding students in preparation for the exhibition, which allows 11 students to embark on a once-in-a-lifetime opportunity to travel to Italy for the 2018 Venice Biennale of Architecture. Their designs will be featured in the "Time Space Existence" exhibit, offering the public a glimpse at the future of airport design. The students are participating in an Airport Design course with Principal in Charge of Design Curt Fentress, FAIA, RIBA, and Alumni Distinguished Professor of Architectur

Oxford Immunotec's T-SPOT®.TB Test Included in the World Health Organization's First-Ever Essential Diagnostics List21.5.2018 22:15Pressmeddelande

OXFORD, United Kingdom and MARLBOROUGH, Mass., May 21, 2018 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company, today announced that the Company's T-SPOT.TB test for tuberculosis (TB) infection has been included in the World Health Organization (WHO) Model List of Essential In Vitro Diagnostics (EDL) - First Edition. The EDL includes the 113 most important tests recommended by WHO for use at various levels of the health care system. These essential diagnostics satisfy the priority health care needs of the population and were selected with due regard to disease prevalence and public health relevance, evidence of efficacy and accuracy, and comparative cost-effectiveness. 58 of the tests listed are for the detection and diagnosis of a wide range of common conditions, providing an essential package that can form the basis for screening and management of patients. The remaining 55 tests are designed for the detection, diagnosis, and moni

Virgin Pulse and RedBrick Health Joining Forces to Create World's Largest Digital Employee Wellbeing and Engagement Company21.5.2018 17:00Pressmeddelande

Merger Will Create First and Only One-Stop-Shop for Employee Health, Wellbeing and Benefits Engagement; Combined Company Will Have More Than 3,300 Customers Across 190 Countries PROVIDENCE, R.I., May 21, 2018 (GLOBE NEWSWIRE) -- Providence-based Virgin Pulse and Minneapolis-based RedBrick Health announced today that the industry pioneers will merge, creating the world's largest, most comprehensive digital health and engagement company. This powerful combination will deliver the industry's only fully integrated digital platform, with benefits navigation and live coaching to support global clients and members across the entire health, wellbeing and benefits lifecycle - from screening and assessment to activation, behavior change and the adoption of sustainable, healthy habits. "We are thrilled to join with RedBrick to set a new vision and standard for employee health, wellbeing and engagement," said David Osborne, Virgin Pulse CEO, who will serve as CEO of the combined company. "Bringing

Hotels.com App Wins 2018 MediaPost Appy Award in Travel & Tourism Category21.5.2018 16:00Pressmeddelande

Developed by EPAM, app is recognized for creativity and excellence in app design NEWTOWN, Pa., May 21, 2018 (GLOBE NEWSWIRE) -- Hotels.com® and EPAM Systems, Inc. (NYSE:EPAM) announced their triumphant win at the 2018 MediaPost Appy Awards in the Travel and Tourism category this week. The Hotels.com mobile app, developed in collaboration with EPAM Systems, Inc., a leading global provider of digital platform engineering and software development services, has been crowned the best app developed for airlines, hotels, travel search engines, destinations, cruises, travel advice or car rentals. With over 70 million downloads and a 4.5+ star rating from consumers on both iOS and Android app stores, the Hotels.com app has now been recognized by the industry leading Appy Awards, which honor creativity and excellence in app design. The app provides a simple, fast and secure way for users to plan, book and manage hotel reservations, and allows travelers to book hundreds of thousands of places to

Karolinska Development's portfolio company Pharmanest appoints new CEO21.5.2018 15:01Pressmeddelande

STOCKHOLM, May 21, 2018. Karolinska Development's portfolio company Pharmanest AB announces the appointment of Helena Jansson as new Chief Executive Officer. Helena is an experienced life science executive, with a proven track record of successful business development and commercialization of pharmaceutical products. She replaces Gunilla Lundmark, who leaves her position after seven years. Helena Jansson has long experience in the life science industry and a broad knowledge base with a focus on business development and commercialization of pharmaceutical portfolios. She has spent a substantial part of her career at Medivir AB, in positions such as Business Unit Director, Head of Supply Chain and Director Alliance Management. In 2017, Pharmanest signed an outlicensing agreement with Gedeon Richter, a leading European pharmaceutical company within women's health. The agreement gives Gedeon Richter the marketing and sales rights to commercialize Pharmanest's first product SHACT (Short Act

Karolinska Development's portfolio company Pharmanest appoints new CEO21.5.2018 15:01Pressmeddelande

STOCKHOLM, May 21, 2018. Karolinska Development's portfolio company Pharmanest AB announces the appointment of Helena Jansson as new Chief Executive Officer. Helena is an experienced life science executive, with a proven track record of successful business development and commercialization of pharmaceutical products. She replaces Gunilla Lundmark, who leaves her position after seven years. Helena Jansson has long experience in the life science industry and a broad knowledge base with a focus on business development and commercialization of pharmaceutical portfolios. She has spent a substantial part of her career at Medivir AB, in positions such as Business Unit Director, Head of Supply Chain and Director Alliance Management. In 2017, Pharmanest signed an outlicensing agreement with Gedeon Richter, a leading European pharmaceutical company within women's health. The agreement gives Gedeon Richter the marketing and sales rights to commercialize Pharmanest's first product SHACT (Short Act

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum